

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **CSPC PHARMACEUTICAL GROUP LIMITED**

**石藥集團有限公司**

*(Incorporated in Hong Kong with limited liability)*

**(Stock Code: 1093)**

### **VOLUNTARY ANNOUNCEMENT FIRST PATIENT DOSED IN THE PHASE 1 CLINICAL TRIAL OF INVESTIGATIONAL NEW DRUG “ALMB-0168”**

The board of directors (the “**Board**”) of CSPC Pharmaceutical Group Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) is pleased to announce that the first patient has been dosed in Australia in a Phase 1 clinical trial of ALMB-0168, a humanized monoclonal antibody developed by AlaMab Therapeutics Inc. (“**AlaMab**”), a subsidiary of the Company.

The study conducted in Australia is a multi-center, first-in-human dose escalation Phase 1 clinical trial with single agent in multiple doses by intravenous injection, which is designed to evaluate the safety, tolerability, pharmacokinetics and preliminary efficacy of ALMB-0168 in patients with bone cancer and bone metastasis. ALMB-0168 is a first-in-class humanized monoclonal antibody agonist for novel target hemichannel Connexin 43 membrane protein, which is independently developed by AlaMab for the treatment of serious diseases with unmet medical needs, including bone cancer, bone metastasis and osteoporosis. ALMB-0168 has been granted orphan-drug designation and rare pediatric disease designation by the U.S. FDA for the treatment of bone cancer in 2019, and clinical trial approvals in Australia and China in 2020.

AlaMab is an innovative biopharmaceutical company in the U.S. dedicated to the research and development of first-in-class antibody drugs. ALMB-0166, another investigational new drug of AlaMab for the same target but with different mechanism, is currently in Phase 1 clinical trial for the treatment of acute spinal cord injury. AlaMab is making unremitting efforts to expedite the research and development progress of these two drug candidates.

By Order of the Board  
**CSPC Pharmaceutical Group Limited**  
**Cai Dongchen**  
*Chairman*

Hong Kong, 28 October 2020

*As at the date of this announcement, the Board comprises Mr. CAI Dongchen, Mr. ZHANG Cuilong, Mr. PAN Weidong, Mr. WANG Zhenguo, Mr. WANG Huaiyu, Dr. LI Chunlei, Dr. WANG Qingxi and Mr. CHAK Kin Man as executive directors; Mr. LEE Ka Sze, Carmelo as non-executive director; and Mr. CHAN Siu Keung, Leonard, Mr. WANG Bo, Prof. LO Yuk Lam, Dr. YU Jinming and Mr. CHEN Chuan as independent non-executive directors.*